Trial Profile
A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Single-Season Study to Assess the Efficacy and Safety of HI-164OV, an Enteric-coated Oral Vaccine Tablet Containing 45 mg HI-164 Active Substance (Inactivated, Whole Cells of Non-typeable Haemophilus influenzae, isolate 164) for Reducing the Rate and Severity of Acute Exacerbations in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs HI 164 (Primary)
- Indications Bacterial infections; Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 28 Jun 2019 Status changed from active, no longer recruiting to completed.
- 28 Jun 2012 Primary endpoint 'Symptom-exacerbation-rate' has not been met.
- 29 May 2012 Status changed from recruiting to active, no longer recruiting, according to a Bioxyne media release.